Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 7, 2010, Pages 393-399

  Freudenberg, L S ^a   Fromke C ^b   Petrich, T ^b   Marlowe, R J ^c   Koska, W W ^a   Brandau, W ^a   Eising, E G ^a   Knust, E J ^a   Bockisch, A ^a   Jentzen, W ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Spencer Fontayne Corporation   (United States)

Author keywords

124 iodine; 131 iodine; computed tomography; differentiated thyroid carcinoma; dosimetry; positron emission tomography; radioiodine; recombinant human thyroid stimulating hormone; remnant dose per administered activity; thyroid hormone withholding; thyroid remnant; thyroid remnant ablation; thyroid remnant dose

Indexed keywords

IODINE 124; IODINE 131; RECOMBINANT THYROTROPIN; THYROID HORMONE; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG SAFETY; EUTHYROIDISM; FEMALE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; SCHOOL CHILD; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; ABLATION THERAPY; BLOOD; CARCINOMA, PAPILLARY; COMPARATIVE STUDY; MIDDLE AGED; RADIATION RESPONSE; RETROSPECTIVE STUDY; THYROID NEOPLASMS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VERY ELDERLY; YOUNG ADULT;

ABLATION TECHNIQUES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID HORMONES; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 77954866328     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1225350     Document Type: Article

References (37)

1. Andermann P, Schlogl S, Mader U, et al. Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound. Nuklearmedizin 2007 46 1-7
2. Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 2006 27 627-632
3. Chianelli M, Todino V, Graziano F, et al. Low dose (2.0GBq; 54mCi) radioiodine postsurgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low risk patients. Eur J Endocrinol 2008 e-publication
4. Eschmann SM, Reischl G, Bilger K, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002 29 760-767
5. th ed Lippincott-Raven, Philadelphia, PA 1997
6. nd ed Springer, Berlin 2005
7. 124I-PET dosimetry in advanced differentiated thyroid cancer. Therapeutic impact. Nuklearmedizin 2007a 46 121-128
8. Freudenberg LS, Jentzen W, Marlowe RJ, et al. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 2007b 115 690-693
9. Furhang EE, Larson SM, Buranapong P, et al. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 1999 40 131-136
10. Gorges R, Eising EG, Fotescu D, et al. Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound 2003 16 191-206
11. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007 92 28-38
12. Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006 47 648-654
13. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999 84 3877-3885
14. Jentzen W, Freudenberg L, Eising EG, et al. Segmentation of PET volumes by iterative image thresholding. J Nucl Med 2007 48 108-114
15. 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2008a 49 1017-1023
16. 124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2008b 35 611-623
17. 124I solutions after thermodistillation of irradiated 124TeO2 targets. Appl Radiat Isot 2000 52 181-184
18. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997 337 888-896
19. 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004 45 619-625
20. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations Society of Nuclear Medicine, New York 1991
21. Luster M, Felbinger R, Dietlein M, et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005 15 1147-1155
22. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003 30 1371-1377
23. rd, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992 33 1132-1136
24. Pacini F, Molinaro E, Castagna MG. Ablation of thyroid residues with 30mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002 87 4063-4068
25. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006 91 926-932
26. Park S-G, Reynolds JC, Brucker-Davis F, et al. Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) vs. hypothyroidism [abstract]. J Nucl Med 1996 37 15P, abstr 49
27. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50mCi) and 3700MBq (100mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007 92 3542-3546
28. 131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients. J Nucl Med 2008 49 1445-1450
29. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002 43 1482-1488
30. 131I is associated with lowered radiotoxicity. J Nucl Med 2008 49 1776-1782
31. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998 338 297-306
32. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006 91 878-884
33. Snyder W, Ford MR, Warner GG, et al. S, Absorbed dose per unit cumulated activity for selected radionuclides and organs Society of Nuclear Medicine, New York, NY 1975
34. Taieb D, Sebag F, Cherenko M, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: a randomized controlled study. Clin Endocrinol (Oxf) 2008 e-publication
35. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008 49 764-770
36. 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. Nucl Med Commun 2007 28 215-223
37. 124I. J Radioanal Nucl Chem Lett 1996 213 253-261